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METHODS: Special clinical methods were used for health
condition evaluation. Our first research of some of the
QoL factors was held in 1996–97.
RESULTS: It was conducted on 561 patients with differ-
ent oncological diseases, including retroperitoneal malig-
nant diseases. The period of remission for 59% of the pa-
tients was 5–10 years, for the rest 41%—5 years. Ages of
the patients varied from 3–7 years to 15 years and over.
Their physical condition was studied (including cardiovas-
cular, urinary, immunological, reproductive, muscular and
other systems), as well as their psychological condition
and social adaptation.
CONCLUSIONS: Only 40% of the patients don’t have
significant after-effect from their anti-tumor therapy. Dys-
function of the immune system was found in 78% of the
examined patients, of the alimentary canal, 67%, of the
central nervous system, 60%, of the muscle and bone and
the urinary tract systems, 56% and 50% respectively. To-
gether with psychological and social problems this consid-
erably influences the QoL of such patients. The research
was continued by the evaluation of life conditions of 278
patients cured from malignant retroperitoneal tumors, as
well as by the analysis of the obtained data in accordance
with the international life-level standards. For this purpose
we are currently adopting the selected interrogatory sheets
EQ-50 (for adult patients) and SP-36 for children. The re-
sults will be introduced in future publications.
PTH3
GUIDELINES FOR SUBMISSION OF REQUESTS 
FOR INCLUSION OF A PHARMACEUTICAL 
PRODUCT IN THE ISRAELI
NATIONAL FORMULARY
Shani S, Morginstin T, Shemer J
Ministry of Health, Jerusalem, Israel
The Israeli National Health Insurance Law enacted in
1995 determines a list of health services including a list of
reimbursed drugs (NLRD). Accordingly, each citizen is
entitled to receive health services of established quality
within the framework of the available resources. In the
last decade, significant advances in R&D have resulted in
the emergence of numerous expensive drugs in the phar-
maceutical market. Hence, the Pharmacoeconomics Unit
at the Pharmaceutical Administration of the Ministry of
Health established a mechanism for updating the NLRD,
based on the evaluation of clinical, epidemiological and
economic data. Prior to the presentation of guidelines for
the pharmaceutical industry on submission of economic
data as part of a request for the inclusion of a pharma-
ceutical product in the NLRD, a survey was conducted to
examine existing pharmacoeconomic knowledge of the
Israeli pharmaceutical industry. The results of the survey
indicated that the pharmaceutical industry has very little
pharmacoeconomic knowledge. These results prompted a
lenient approach to the submission of requests for the
next two years during which the industry is expected to
develop a firm pharmacoeconomic basis. Guidelines on
submission of a request to include a pharmaceutical
product in the NLRD were presented to the pharmaceuti-
cal industry. The dossier to be submitted by the industry
consists of three sections:
Clinical—treatment regimens, adverse effects, effi-
cacy and safety in comparison to alternate therapies.
Epidemiological—morbidity figures, definition of tar-
get population, sales figures.
Economic—cost of the suggested treatment compared
to that of alternative therapies and an economic evalu-
ation.
260 different requests have been submitted for the 2000
update of the NLRD, according to the guidelines, and are
currently being processed. Following the 2000 update, a
reassessment will take place, and the guidelines will be
changed according to the experience incurred by both the
industry and the Ministry of Health.
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ECONOMIC EVALUATION BY UK 
PHARMACEUTICAL AND MEDICAL DEVICE 
FIRMS: GENERAL TRENDS AND
POLICY IMPLICATIONS
Cookson R
LSE Health, London School of Economics, London, UK
OBJECTIVES: To survey expert opinion on trends in
economic evaluation by UK pharmaceutical and medical
device firms, from R&D to product launch and beyond.
The background is the move in some EU countries, exem-
plified by NICE in UK, towards emulating the Australian
“fourth hurdle” of mandatory economic data require-
ments before pharmaceutical purchasing.
METHODS: Interviews with a range of experts from UK
industry and academia. Industry representatives included
both science experts and policy experts from six pharma-
ceutical firms and four medical device firms; academics
included both health economists and pharmaceutical pol-
icy specialists.
RESULTS: Dramatic increase over the last decade in pro-
duction of pharmacoeconomic evidence at late develop-
ment and early marketing stages in response to more ag-
gressive management of pharmaceutical budgets. Medical
device firms lag behind, due to smaller size and less aggres-
sive purchasers, but large firms are now starting to design
trials with economic evaluation in mind. Limited improve-
ment in scientific quality of pharmacoeconomic evidence
in relation to state-of-the-art methodology (“Washington
Guidelines”); limited use of effectiveness trials, utility indi-
ces, cost-utility analysis, sensitivity analysis. Limited use of
prospective cost-effectiveness modeling in R&D go/no go
decisions, even though prospective modelling of return
on investment is routinely used from early development
onwards. Some industry representatives argue that phar-
macoeconomics cannot be used to prioritize R&D since
“hard” data are not available and uncertainties are great.
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Some academic economists disagree, however, arguing
that prospective economic modelling is better than infor-
mal opinion.
CONCLUSIONS: This study raises doubts about whether
pharmacoeconomics has yet had much impact on R&D
prioritization. If pharmacoeconomics is to succeed in guid-
ing firms towards developing cost effective new products
(i.e., ones delivering greater population health gains per
unit of cost than existing products), then firms may need
stronger incentives to use prospective cost-effectiveness
modeling in R&D decisions.
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A COST-MINIMIZATION ANALYSIS OF IRON 
DEFICIENCY ANEMIA TREATMENT
Vorobiev PA1, Gorokhova SG1, Avxentieva MV1, Kobina SA2
1Moscow Medical Academy named after I.M.Sechenov, 
Moscow, Russia; 2Rhône-Poulenc Rorer, Moscow, Russia
OBJECTIVES: To compare the costs of baseline standard
treatment course for iron deficiency anemia with differ-
ent Fe-content medicines.
METHODS: The model for non-complicated iron defi-
ciency anemia treatment was worked out by experts in
the field of hematology: a course of 200 mg Fe daily
for 28 days. There were 5 Fe-content medicines avail-
able in Moscow pharmacies conventionally named H, S,
T, F, G with the same suggested clinical effectiveness. Ac-
tive Fe amount per tablet, necessary mean dose of
drug, mean duration of course treatment, drug price were
taken into account. Data on medicine prices was calcu-
lated as a mean value according to price-lists of Moscow
pharmacies derived from the Internet on April, 20, 1999.
RESULTS: The table below shows the results of this cost-
minimization analysis.
CONCLUSION: The course of treatment for iron defi-
ciency anemia with F-drug that is the cheapest really is
the most expensive. Cost-saving courses are those with S
and G-drugs. Although it is traditionally used in Russia,
price per pack shouldn’t be an economical criteria for
choice of treatment.
PTH6
PATIENTS’ PERCEPTIONS OF THE OUTCOMES 
OF TREATMENT WITH TOPICAL NSAIDS, 
RUBIFACIANTS AND ORAL PAIN REMEDIES. A 
PROSPECTIVE STUDY OF MEDICINES 
AVAILABLE THROUGH
COMMUNITY PHARMACIES
McNaughton D, Libby G, MacDonald T
Medicines Monitoring Unit, Ninewells Hospital, Dundee, 
Scotland
OBJECTIVES: To examine patients’ attitudes to and expe-
riences of NSAIDs, Rubifaciants and oral pain remedies.
METHODS: Subjects were recruited in one of 30 phar-
macies in Scotland representing rural, semi-rural and ur-
ban environments. Subjects who had purchased an Over
the Counter medicine from one of three Topical NSAIDs,
three Rubifaciants or one of four oral pain remedies were
asked to participate in a questionnaire based study. The
questionnaire examined pain assessment pre and post
treatment, side effects experienced, patients’ expectations
of treatment, treatment outcomes, opinion about the rel-
ative merits of the three groups of medicines and demo-
graphic data about the purchaser. The questionnaires
were anonymous but identified the study pharmacy. In-
formation about the effectiveness of different rates of re-
cruitment was also obtained. After an initial emphasis on
pharmacist inducements, the study pharmacist was sta-
tioned in the pharmacies and achieved a high rate of re-
cruitment and returned questionnaires.
RESULTS: Of 430 questionnaires distributed, 302
(70.23%) were returned; 13 patients were excluded due to
spoiled questionnaires. Of the remaining 289 patients, 94
(32.5%) purchased Topical NSAIDs, 105 (36.6%) Rubifa-
ciants and 90 (31.1%) purchased oral remedies. There was
no significant difference between the three groups in pain
scores pre and post treatment (p  0.22). There was a dif-
ference in choice of treatment type by age (p  0.021) with
patients aged over 60 more likely to choose a Topical
NSAID. Those who suffered symptoms less than once a
week and those choosing a Topical NSAID were more
likely to be first time users of the study treatment (both p 
0.001). Those in the Topical NSAID group were also more
likely to report that they would definitely buy the product
again than those in the other treatment groups (p  0.014).
CONCLUSIONS: Initial findings demonstrate a very low
level of adverse events and a high rate of satisfaction par-
ticularly with Topical NSAIDs as represented by a greater
willingness to buy again.
PTH7
GLOBAL SCALE VERSUS GENERIC AND 
DISEASE-SPECIFIC INSTRUMENTS TO 
MEASURE THE HEALTH STATUS OF PATIENTS 
WITH ASTHMA
Hajiro T, Nishimura K, Tsukino M, Oga T
Department of Respiratory Medicine, Graduate School of 
Medicine, Kyoto University, Kyoto, Japan
Indicators
Conventionally named drugs
H S T F G
Fe mg/tab 10 100 80 45 100
Equivalent daily dose
(200 mg daily) tab 20 2 3 5 2
Price per pack USD* 2.06 3.18 4.42 0.95 1.53
Tablet number per pack 100 50 30 10 30
Price per tablet USD 0.02 0.06 0.15 0.01 0.05
Cost per course of 
treatment (28 days) 11.5 3.56 12.38 13.3 2.86
USD 4
*Prices in rubles were converted into USD according to the Central Bank rate
on April 20, 1999
